Merck has agreed to buy EyeBio for up to $3B, Ian Johnston and Oliver Barnes of The Financial Times reports. The deal will involve a $1.3B upfront payment and a further $1.7B dependent on milestones, UK venture capitalist Kate Bingham and EyeBio CEO David Guyer told the Times.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- M&A: Merck (MRK) Nears Deal to Bolster Eye-care Portfolio
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 05/17/2024
- Merck discontinues vibostolimab-Keytruda combination arm of Phase 3 trial
- Merck provides update on Phase 3 KEYNOTE-B21 trial
- CytomX Therapeutics, Merck enter CX-801 trial collaboration
Questions or Comments about the article? Write to editor@tipranks.com